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The integration of knowledge concerning the regulation of MT, a highly conserved, low molecular weight, cystein-rich
metalloprotein, on its proposed functions is necessary to clarify how MT aﬀects cellular processes. MT expression is
induced/enhanced in various tissues by a number of physiological mediators. The cellular accumulation of MT depends on the
availability of cellular zinc derived from the diet. MT modulates the binding and exchange/transport of heavy metals such as zinc,
cadmium, or copper under physiological conditions and cytoprotection from their toxicities, and the release of gaseous mediators
suchas hydroxyl radicals or nitricoxide. Inaddition, MTreportedly aﬀects anumber of cellular processes,such as gene expression,
apoptosis, proliferation, and diﬀerentiation. Given the genetic approach, the apparently healthy status of MT-deﬁcient mice argues
againstanessentialbiological roleforMT;however, thismolecule maybecritical incells/tissues/organsintimesofstress,sinceMT
expression is also evoked/enhanced by various stresses. In particular, because metallothionein (MT) is induced by inﬂammatory
stress, its roles in inﬂammation are implied. Also, MT expression in various organs/tissues can be enhanced by inﬂammatory
stimuli, implicating in inﬂammatory diseases. In this paper, we review the role of MT of various inﬂammatory conditions.
Copyright © 2009 Ken-ichiro Inoue et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Metallothioneins (MTs) discovered as cadmium-binding
protein from horse kidney approximately ﬁve decades ago,
and were later characterized as a low molecular weight
protein with a high cysteine content and a high aﬃnity
for divalent important metals, such as zinc and copper,
and unimportant ones, such as cadmium and mercury
(Margoshes) [1]. Because of their high metal content
and unusual bioinorganic structure, they are classiﬁed as
metalloproteins [2]. MTs are unusually rich in cysteine
residues that coordinate multiple zinc and copper atoms
under physiological conditions.
2. Classiﬁcation
In mice, there are 4 MT genes that reside in a 50-kb
region on chromosome 8 [3]. The mouse MT-I and–II genes
are expressed at all stages of development in many cell
types of most organs; they are coordinately regulated by
metals, glucocorticoids, and inﬂammatory stress [4]. MT-
III is expressed predominantly in not only neurons but
also in glia and male reproductive organs [5–7]. MT-IV
is expressed in diﬀerentiating stratiﬁed squamous epithelial
cells [3]. All four MT genes are expressed in the maternal
deciduum [8]. In humans, whereas, MTs are encoded by a
family of genes consisting of 10 functional MT isoforms, and
the encoded proteins are conventionally subdivided into 4
groups: MT-1, MT-2, MT-3, and MT-4 proteins [9]. While
a single MT-2A gene encodes MT-2 protein, MT-1 protein
comprises many subtypes encoded by a set of MT-1 genes
(MT-1A, MT-1B, MT-1E, MT-1F, MT-1G, MT-1H, and MT-
1X), accounting for the microheterogeneity of the MT-1
protein [2]. As shown above, there are multiple MT genes,
expressed in distinct patterns, suggesting that they possess
important functions; however, whether they have redun-
dant or divergent functions under both physiological and
pathological conditions is not fully understood, although the
known functions of MTs include metalloregulatory roles in
cell growth, diﬀerentiation, and apoptosis and the enhanced2 Mediators of Inﬂammation
synthesis of MTs in rapidly proliferating tissues, implying
their crucial role in normal and neoplastic cell growth [10].
3.Characteristics
Theseintracellularproteinsarecharacterizedbytheirunusu-
ally high cysteine content (30%) and lack of aromatic
amino acids. Because of their thiol rich content, MTs
can bind to a number of trace metals such as cadmium,
mercury, platinum, and silver, and protect cells and tissues
against the toxicity of these metals. Furthermore, MTs are
among the most abundant components interacting with the
biologically essential metals zinc and copper. MT metal-
thiolate fractions, being dynamic and of a high aﬃnity, also
facilitate metal exchange in tissues [11].
MTs are present in a great variety of eukaryotes [12],
functioning as antioxidants; they also play a protective role
against hydroxyl-free radicals. This is relevant in tumors
which are known to be markedly radiosensitive, where
radiotherapy is the treatment of choice [13].
4. Functionunder Physiological Conditions
The putative functions of MT include intracellular metal
metabolism and/or storage, metal donation to target
apometalloproteins (especially zinc ﬁnger proteins and
enzymes), metal detoxiﬁcation, and protection against oxi-
dants and electrophils [14]. Evidence for these functions
originally came from traditional animal, cell culture, and
in vitro models. Furthermore, these studies have been
supportedbyexperiments using murine models withthetar-
geteddeletionortransgenicoverexpressionofMTgenes.MT
most likely functions in the regulation of zinc metabolism
[14]. Elevations of dietary zinc induce/enhance intestinal
MT [15], whereas maximal intestinal Zn accumulation
seems to depend on MT synthesis [16]. MT (−/−)m i c e
accumulate less zinc in the distal gastrointestinal tract when
fed a high zinc diet [17]. In most studies, zinc absorption
was inversely related to the intestinal MT content after
MT was induced by dietary, parenteral zinc, or by fasting
[14]. Studies using transgenic and knockout mice have
conﬁrmed that MT can alter the processing of zinc taken
orally because the serum zinc concentration was inversely
related to the intestinal MT level in these mice after single
oral doses of zinc [17, 18]. In turn, urinary Zn excretion
levels measured during a fast or Zn intake restriction were
greater in MT (−/−) mice than in MT (+/+) mice [19].
As well, the increase in hepatic Zn concentration after the
administrationoflipopolysaccharide(LPS)wasfoundinMT
(+/+) but not in MT (−/−)m i c e[ 20]. These results suggest
that MT has the ability to retain Zn under physiological
and pathological conditions. On the other hand, tissue
Zn concentration was reduced, and the sensitivity to Zn
deﬁciency during pregnancy was enhanced in MT (−/−)
mice [21], and further, Zn deﬁciency caused abnormalities
in neonate kidney diﬀerentiation in MT (−/−)m i c e[ 22].
Conversely, in MT-transgenic mice, Zn was accumulated in
female organs, and the teratogenicity of Zn deﬁciency during
pregnancy was signiﬁcantly ameliorated. Taken together, MT
is likely to have a Zn metabolizing activity in the individual
level [23].
Besides, MT demonstrates strong antioxidant properties.
MT protein levels in rodent liver [24, 25] and mRNA levels
in hepatic cell lines [26] are increased following injection
with compounds that result in free radical formation, for
example, carbon tetrachloride, menadione, or paraquat. An
injection of ferric nitrilotriacetate, which produces reactive
oxygen species (ROS), induces transcriptional level of MT
in the liver and kidney [27]. These ﬁndings suggest that MT
plays a role in oxidative stress. Consistent with this, MT is
able to scavenge a wide range of ROS including superoxide,
hydrogen peroxide, hydroxyl radicals, and nitric oxide [19,
28,29].Inparticular,ithasbeenshownthattheabilityofMT
to capture hydroxyl radicals, which are primarily responsible
for the toxicity of ROS, is three hundred-times greater than
that of glutathione [30], the most abundant antioxidant
in the cytosol [19]. Further, metal-thiolate clusters are
reportedly oxidized in vitro; thus, they could scavenge
deleterious oxygen radicals. Compelling genetic evidence for
this concept comes from work using yeast. In brief, yeast that
cannot synthesize copper MTs are more sensitive to oxidative
stress if they also lack superoxide dismutase, suggesting that
yeast MT has antioxidant functions [31]. In addition, the
expression of monkey MTs under the control of the yeast
MT promoter also protects against oxidative stress [31].
Manyagentsthatinduceoxidativestress,suchaschloroform,
turpentine, diethyl maleate, paraquat, and H2O2, can also
induce MT-I and MT-II in vitro and in vivo [24, 26, 32].This
strongly suggests that MT is involved in protecting against
oxidative damage. Conversely, mammalian cells that express
excess MTs appear to be resistant to the toxic eﬀects of
nitricoxide[33]andmanyelectrophilicantineoplasticagents
[34], which are capable of reacting with the cysteines of MT.
Further, relatively recent studies have demonstrated that MT
is induced by oxidative stress-producing chemicals [35], and
exhibits cytoprotection against oxidative stress-related organ
damage in vivo [36, 37].
Despite the conﬁrmed roles of MT under physical condi-
tions,asmentionedabove,acompleteidentiﬁcationofallthe
functionsofthisuniqueproteinwithinanintegrativecontext
has yet to emerge, particularly under pathophysiological
conditions. Particularly, since proinﬂammatory cytokines
including interleukin (IL)-1, IL-6, and interferon-γ also
induce hepatic MT gene expression in vivo [38–40], the roles
of MT in inﬂammation have been focused on. There are
conﬂicting reports about the role of MT in inﬂammatory
processes. In fact, MT (−/−) mice were resistant to tumor
necrosis factor (TNF)-induced lethal shock compared to
MT (+/+) mice [38]. MT-I-overexpressing mice are more
sensitive to the lethal eﬀects of TNF than MT (+/+) mice
[38]. In contrast, Kimura et al. have reported that MT
(−/−) mice are more susceptible to LPS-induced lethal
shock in D-galactosamine (GalN)-sensitized mice through
the reduction of alpha (1)-acid glycoprotein than MT (+/+)
mice [41]. Accordingly, it seems that the roles of MT in
inﬂammation depend on pathophysiologic conditions (site,
route of stimuli, and type).Mediators of Inﬂammation 3
Whereas, to date, inﬂammatory diseases such as sys-
temic inﬂammatory response syndrome including acute
lung injury, allergic asthma, oxidative lung injury, and
acute liver injury are as yet refractory and/or hindering
daily life, possibly due to the incomplete understanding of
molecular targets. Thus, investigation for the role of MT
in these inﬂammatory diseases may provide hint for novel
therapeutic options.
5. Function of MT under Pathophysiological
Conditions in Inﬂammation
5.1. Role of MT in Lung Injury Related to LPS. Previous as
well as our recent studies have shown the expression of MT
in the lung [39, 42]. Immunohistopathological examination
led to the detection of immunoreactive MT-I/II proteins in
the lungs in endothelial and alveolar epithelial cells of MT
(+/+) mice, whereas they were not detected in those of MT
(−/−) mice. Furthermore, the expression was conﬁrmed to
be enhanced by oxidative stimuli like LPS and ozone (O3)
exposure (data not shown).
The intratracheal instillation of LPS produces a well-
recognized model of acute lung injury, leading to the
activation of alveolar macroghages, tissue inﬁltration of neu-
trophils, and interstitial edema [43]. Although the inhalation
of LPS has been reported to induce MT expression in the
lunginvivo[39,42],thereisnoevidenceregardingthedirect
contribution of MT in acute lung injury related to LPS.
MT (−/−) and MT (+/+) mice were administered
vehicle or LPS (125μg/kg) intratracheally. Thereafter, the
cellular proﬁle of the bronchoalveolar lavage (BAL) ﬂuid,
pulmonary edema, lung histology, expression of proinﬂam-
matorymolecules,and nuclear localization of nuclear factor-
κ B( N F - κ B) in the lung were evaluated. As a result,
MT (−/−) mice were more susceptible than MT (+/+)
mice to neutrophilic lung inﬂammation and lung edema,
which was induced by intratracheal challenge with LPS.
After LPS challenge, MT deﬁciency enhanced the vacuolar
degeneration of pulmonary endothelial and type I alveolar
epithelial cells, and caused a focal loss of the basement
membrane. However, unexpectedly, LPS treatment induced
no signiﬁcant diﬀerences neither in the enhanced expression
of proinﬂammatory cytokines and chemokines, nor in the
activation of the NF-κ B pathway in the lung between
the two genotypes. Lipid peroxide levels in the lungs were
signiﬁcantly higher in LPS-treated MT (−/−) than LPS-
treated MT (+/+) mice. These ﬁndings suggest that MT
protects against acute lung injury related to LPS. The eﬀects
are possibly mediated via the enhancement of pulmonary
endothelial and epithelial integrity, not via inhibition of the
NF-κ Bp a t h w a y[ 44].
Next, MT (−/−) and MT (+/+) mice were adminis-
tered vehicle or LPS (30mg/kg) intraperitoneally. There-
after, coagulatory parameters, organ histology (lung, liver,
and kidney), and the local expression of proinﬂammatory
molecules were evaluated. As a result, compared with
MT (+/+) mice, MT (−/−) mice showed a signiﬁcant
prolongation of the prothrombin time (PT) and activated
partial thromboplastin time (APTT), a signiﬁcant increase
in the levels of ﬁbrinogen and ﬁbrinogen/ﬁbrin degradation
products, and a signiﬁcant decrease in activated protein
C, after LPS treatment. LPS induced inﬂammatory organ
damage in the lung, kidney, and liver in both genotypes
of mice. The damage including neutrophil inﬁltration in
the organs was more prominent in MT (−/−) than MT
(+/+) mice after LPS treatment. In both genotypes of
mice, LPS enhanced the protein expression of interleukin
(IL)-1β, IL-6, granulocyte/macrophage-colony-stimulating
factor, macrophage inﬂammatory protein (MIP)-1α,M I P -
2, macrophage chemoattractant protein-1, and keratinocyte-
derived chemoattractant (KC) in the lung, kidney, and liver
and circulatory levels of IL-1β, IL-6, MIP-2, and KC. In
overall trends, however, the levels of these proinﬂammatory
proteins were greater in MT (−/−) than in MT (+/+)
mice after LPS challenge. Our results suggest that MT
protects against coagulatoryand ﬁbrinolytic disturbance and
multiple organ damage including lung injury induced by
LPS, at least partly, via inhibition of the local expression
of proinﬂammatory proteins in this model (Figure 1)[ 45].
Nonetheless, its underlying mechanistic pathways including
new ones (e.g., Toll-like receptors [46], NALP inﬂamma-
somes [47], neurotensin [48], RANK-RANKL [49]) remain
to be explored in future.
5.2. Role of MT in Allergic Inﬂammation. Bronchial asthma
is a complex syndrome, characterized by obstruction, hyper-
responsiveness, and persistent inﬂammation of the airways.
Inﬂammation in asthma is characterized by an accumula-
tion of eosinophils, lymphocytes, and neutrophils in the
bronchial wall and lumen [50–52]. The mechanisms via
which inﬂammatory cells alter airway function in asthmatic
conditions include the release of Th2 cytokines (IL-4, IL-
5, and IL-13) and chemotactic mediators such as thymus
and activation-regulated chemokine, macrophage-derived
chemokine, and eotaxin, and various proteases as well as
the generation of reactive oxygen species. Thus, next, we
determined the role of MT in allergic airway inﬂammation
induced by ovalbumin (OVA) using MT (−/−)m i c e .M T
(−/−) and MT (+/+) mice were intratracheally challenged
withOVA(1μg/body)biweekly3times.Thereafter,thecellu-
lar proﬁle of the BAL ﬂuid, lung histology, and expression of
proinﬂammatory molecules in the lung were evaluated. After
the ﬁnal OVA challenge, signiﬁcant increases were noted in
the numbers of total cells, eosinophils, and neutrophils in
B A Lﬂ u i di nM T( −/−) mice compared to those in MT
(+/+) mice. Histopathologically, in the presence of OVA,
the number of inﬂammatory cells including eosinophils
and neutrophils in the lung was larger in MT (−/−)
than in MT (+/+) mice. The protein level of IL-1β was
signiﬁcantly greater in MT (−/−) than in MT (+/+) mice
after OVA challenge. Immunohistochemistry showed that
the formations of 8-hydroxy-2 -deoxyguanosine, a proper
marker of oxidative DNA damage, and nitrotyrosine in the
lung were more intense in MT (−/−) than in MT (+/+) mice
after OVA challenge. These results indicate that endogenous
MTprotectsagainstallergicairwayinﬂammationinducedby4 Mediators of Inﬂammation
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Figure 1: Hypothesized mechanisms of cytoprotection of MT in LPS-related inﬂammation. Figure reproduced with some modiﬁcations
with permission from FASEB journal [45].
OVA, at least partly, via suppression of the enhanced lung
expression of IL-1β and via its antioxidative potential [53].
5.3. Role of MT in Oxidative Lung Injury. Ozone (O3)i sa
highly toxic principal oxidant found in urban environments
throughout the world. Experimental research has shown that
O3 inhalation causes airway inﬂammation/injury in vivo
[54]. Furthermore, O3 is a strong oxidizing agent that can be
rapidly converted into a number of ROS, including hydrogen
peroxide [55, 56]. In fact, O3-induced lung inﬂamma-
tion/injury comprises oxidative stress-related tissue injury
[57–59]. Also, O3 exposure reportedly results in oxidative
stress in the airway, possibly through the disruption of iron
homeostasis [59]; iron can increase oxidant generation after
O3 interaction with aqueous media and produce hydroxyl
radicals[60,61].Ontheotherhand,lungexpressionofMTis
reportedly induced by O3 exposure in vivo [62, 63]. Thus, we
next examined the role of MT in lung inﬂammation induced
by subacute exposure to O3 using MT (−/−)m i c e .A f t e r
subacute exposure to O3 (0.3ppm), the cellular proﬁle of
BAL ﬂuid, pulmonary edema, lung histology, and expression
of proinﬂammatory molecules in the lung were evaluated.
Exposure to O3 induced lung inﬂammation and enhanced
vascular permeability, which was signiﬁcantly greater in MT
(−/−) than in MT (+/+) mice. Electron microscopically, O3
exposure induced the vacuolar degeneration of pulmonary
endothelial and epithelial cells, and interstitial edema with
focal loss of the basement membrane, which was more
prominentinMT(−/−)thaninMT(+/+)mice.O3-induced
lungexpressionofIL-6wassigniﬁcantlygreaterinMT(−/−)
than in MT (+/+) mice; however, lung expression of the
chemokines such as eotaxin, macrophage chemoattractant
protein-1, and keratinocyte-derived chemoattractant was
comparable between both genotypes of mice in the presence
of O3. Following O3 exposure, the formation of oxidative
stress-related molecules/adducts, such as heme oxygenase-1,
inducible nitric oxide synthase, 8-OHdG, and nitrotyrosine
in the lung was signiﬁcantly greater in MT (−/−) than
in MT (+/+) mice. Collectively, MT protects against O3-
induced lung inﬂammation, at least partly, via the regulation
of pulmonary endothelial and epithelial integrity and its
antioxidative property (64).
5.4. Role of MT in Lethal Liver Injury. Liver has high levels of
Zn-andCu-boundMTandhasahighcapacitytoregenerate.
MT is reportedly involved in hepatocyte regeneration after
partial hepatectomy [64–67] and chemical injury [68].
Similarly, previous studies have shown that induction of MT
canprotectanimals fromhepatotoxicity ofseveralchemicals,
such as ethanol, carbon tetrachloride, acetaminophen, and
cadmium [69].
Hepatic dysfunction due to liver disorders such as viral
hepatitis, liver cirrhosis, and hepatocellular carcinoma is
frequently associated with lethal coagulopathy such as DIC.
Kimura et al. previously reported that MT is protective
against acute liver injury induced by LPS/D- GalN through
the suppression of TNF-α production/release using MT
(−/−)m i c e[ 41]. An animal model of acute (lethal) liver
injury using LPS/D-GalN develops severe coagulopathy with
histological evidence of DIC [70] quite similar to that inMediators of Inﬂammation 5
humans. Furthermore, most coagulatory factors as well as
MT are produced mainly in the liver, indicating a possible
role of MT in the pathogenesis of hepatic disorder-related
coagulopathy.Besides,ourabovementionedstudyhasimpli-
cated MT in pathophysiology of coagulatory disturbance
[45]. To expand the ﬁndings by Kimura et al., therefore,
we explored the role of MT in coagulatory disturbance
during acute liver injury induced by LPS/D-GalN. Both MT
(−/−) and MT (+/+) mice were injected intraperitoneally
with 30μg/kg of LPS and 800mg/kg of D-GalN dissolved
in vehicle. Five hours after the injection, blood samples
were collected and platelet counts and coagulatory param-
eters were measured. LPS/D-GalN challenge signiﬁcantly
decreased platelet number in both genotypes of mice in a
time-dependent fashion as compared to vehicle challenge.
However, in the presence of LPS/D-GalN, the decrease was
signiﬁcantly greater in MT (−/−) than in MT (+/+) mice.
LPS/D-GalN challenge caused prolongation of the plasma
coagulatory parameters such as PT and APTT in both
genotypes of mice as compared with vehicle challenge. In
the presence of LPS/D-GalN, PT and APTT were longer in
MT (−/−) than in MT (+/+) mice. The level of ﬁbrinogen
signiﬁcantly decreased 5 hours after LPS/D-GalN challenge
in both genotypes of mice as compared to vehicle challenge.
After LPS/D-GalN challenge, the level was signiﬁcantly lower
in MT (−/−) than in MT (+/+) mice. As compared to
vehicle administration, LPS/D-GalN administration elicited
an increase in the plasma level of von Willebrand factor in
both genotypes of mice. Further, in the presence of LPS/D-
GalN, the level was signiﬁcantly greater in MT (−/−) than in
MT (+/+) mice ([71].
6. Conclusion
MTs play important roles in the physiological condition,
such as heavy metal homeostasis and radical scavenging.
Furthermore, through a genetic approach, MT has been
shown to protect against various types of (including LPS-
related, allergic, and oxidative) inﬂammatory conditions
in mice, implicating MT-induction/enhancement and/or
zinc supplementation to induce/enhance MT as possible
therapeutic options for inﬂammatory diseases, although
additional research is needed to conclude its clinical utility.
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